VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107

Vaccine Information

Vaccine Name: Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007436
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
MAGE-1 gene engineering:
- Type: Recombinant protein preparation
- Description: (Wen et al., 2019)
- Detailed Gene Information: Click Here.
ERBB2 gene engineering:
- Type: Recombinant protein preparation
- Description: (Wen et al., 2019)
- Detailed Gene Information: Click Here.
gp100 (PMEL) gene engineering:
- Type: Recombinant protein preparation
- Description: (Wen et al., 2019)
- Detailed Gene Information: Click Here.
DCT gene engineering:
- Type: Recombinant protein preparation
- Description: (Wen et al., 2019)
- Detailed Gene Information: Click Here.
AIM2 gene engineering:
- Type: Recombinant protein preparation
- Description: (Wen et al., 2019)
- Detailed Gene Information: Click Here.
IL3RA gene engineering:
- Type: Recombinant protein preparation
- Description: (Wen et al., 2019)
- Detailed Gene Information: Click Here.
Description: A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells. (NCIT_C124054).

Host Response

References

NCIT_C124054: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C124054]

Wen et al., 2019: Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019; 25(19); 5799-5807. [PubMed: 31320597].